<p>Glioma is one of the most malignant tumors in the brain, with high tumor heterogeneity. Traditional treatment methods, such as surgery, radiotherapy and chemotherapy, face numerous challenges and still pose serious threats to human health. Therefore, it is urgent to explore new treatment directions. The immune checkpoint B7-H3 has attracted much attention due to its significant immunomodulatory function in various cancers. Studies have shown that it is highly expressed in glioma and lowly expressed in normal brain tissue. It not only has immunosuppressive function and induces immune escape in glioma, but also promotes the proliferation, migration and angiogenesis of glioma cells. Moreover, there are many immunotherapy strategies targeting B7-H3, such as monoclonal antibodies, antibody-drug conjugates (ADC) and chimeric antigen receptor T-cell (CAR-T) therapy. Therefore, B7-H3 is regarded as a potential target for glioma immunotherapy. This article systematically reviews the occurrence and development process of B7-H3 in glioma, changes in the immune microenvironment, and related treatment methods. Through analysis of several databases such as TCGA, CTPAC, HPA and GEPIA, this study explores the expression of B7-H3 in glioma, its correlation with prognosis and its correlation with the glioma immune microenvironment, providing a new research target for the diagnosis and treatment of glioma.</p>